ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

被引：228

作者：

Cang, Shundong ^{[1
]}

Iragavarapu, Chaitanya ^{[2
,3
]}

Savooji, John ^{[2
,3
]}

Song, Yongping ^{[4
,5
]}

Liu, Delong ^{[4
,5
]}

机构：

[1] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou 450052, Peoples R China

[2] Westchester Cty Med Ctr, Dept Med, Valhalla, NY 10595 USA

[3] New York Med Coll, Valhalla, NY 10595 USA

[4] Zhengzhou Univ, Henan Canc Hosp, Zhengzhou 450052, Peoples R China

[5] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450052, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2015年 / 8卷

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; IN-VIVO EFFICACY; BISPECIFIC ANTI-CD30/CD16A ANTIBODY; ACUTE MYELOID-LEUKEMIA; BH3 MIMETIC ABT-263; FAMILY PROTEINS; CELL-DEATH; HEMATOLOGICAL MALIGNANCIES; NUCLEAR EXPORT;

D O I：

10.1186/s13045-015-0224-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 ( venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.

引用

页数：8

共 95 条

[1] Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo [J].

Ackler, S. ;

Mitten, M. J. ;

Chen, J. ;

Clarin, J. ;

Foster, K. ;

Jin, S. ;

Phillips, D. C. ;

Schlessinger, S. ;

Wang, B. ;

Leverson, J. D. ;

Boghaert, E. R. .

BRITISH JOURNAL OF PHARMACOLOGY, 2012, 167 (04) :881-891

[2] ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo [J].

Ackler, Scott ;

Xiao, Yu ;

Mitten, Michael J. ;

Foster, Kelly ;

Oleksijew, Anatol ;

Refici, Marion ;

Schlessinger, Sally ;

Wang, Baole ;

Chemburkar, Sanjay R. ;

Bauch, Joy ;

Tse, Christin ;

Frost, David J. ;

Fesik, Stephen W. ;

Rosenberg, Saul H. ;

Elmore, Steven W. ;

Shoemaker, Alex R. .

MOLECULAR CANCER THERAPEUTICS, 2008, 7 (10) :3265-3274

[3] The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo [J].

Ackler, Scott ;

Mitten, Michael J. ;

Foster, Kelly ;

Oleksijew, Anatol ;

Refici, Marion ;

Tahir, Stephen K. ;

Xiao, Yu ;

Tse, Christin ;

Frost, David J. ;

Fesik, Stephen W. ;

Rosenberg, Saul H. ;

Elmore, Steven W. ;

Shoemaker, Alexander R. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (05) :869-880

[4] The Bcl-2 protein family: Arbiters of cell survival [J].

Adams, JM ;

Cory, S .

SCIENCE, 1998, 281 (5381) :1322-1326

[5] Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics [J].

Akinleye, Akintunde ;

Avvaru, Parthu ;

Furqan, Muhammad ;

Song, Yongping ;

Liu, Delong .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6

[6] Ibrutinib and novel BTK inhibitors in clinical development [J].

Akinleye, Akintunde ;

Chen, Yamei ;

Mukhi, Nikhil ;

Song, Yongping ;

Liu, Delong .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6

[7] MEK and the inhibitors: from bench to bedside [J].

Akinleye, Akintunde ;

Furqan, Muhammad ;

Mukhi, Nikhil ;

Ravella, Pavan ;

Liu, Delong .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6

[8]

[Anonymous], ASCO M ABSTR S

[9]

[Anonymous], BLOOD

[10]

[Anonymous], ASCO M ABSTR S

← 1 2 3 4 5 6 7 8 9 10 →